Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Päätekijä: | Paul, Pulock |
---|---|
Muut tekijät: | Azam,Faruque |
Aineistotyyppi: | Opinnäyte |
Kieli: | English |
Julkaistu: |
Brac University
2024
|
Aiheet: | |
Linkit: | http://hdl.handle.net/10361/23954 |
Samankaltaisia teoksia
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
Tekijä: Rahman, Tasnim
Julkaistu: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
Tekijä: Hoque, Ismoth Ara
Julkaistu: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
Tekijä: Karim, Samia Binte
Julkaistu: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
Tekijä: Flora, Sanzida Alam
Julkaistu: (2024) -
A review on targeted therapies for lung cancer
Tekijä: Ashraf, Anushey
Julkaistu: (2023)